natural pharmaceuticals derived From Cannabis and other medicinal plants
Company Receives Health Canada Phase 3 Clinical Trial Approval For Smokable Dried Cannabis Prescription Drug
BREAKING: Good Life Networks Inc. increases second quarter revenue year over year by 123% to $3,435,835
- Q2 revenue increased 123% to $3,435,835 from same quarter last year
- Reported net income of $252,712, compared to a net loss of $353,632 in the same quarter last year
- “Our year over year revenue growth for the second quarter was exceptional and further supports our projected revenue and earnings objectives for the full fiscal year,” said Jesse Dylan, GLN President and CEO WATCH OUR RECENT INTERVIEW
Guy Chamberland , Ph.D
Dr. Guy Chamberland, M.Sc., Ph.D., Master Herbalist, has been Chief Scientific Officer & Regulatory Affairs of Tetra Bio-Pharma since June 2016. He has been Vice President of Regulatory Affairs & Product Development at Biotanika Health Group Inc. since March 2007. He served as Vice President of Clinical & Regulatory Affairs at Victhom Laboratory Inc. from 2005 to 2007. He developed a specialty in regulatory affairs (drugs, biologics, medical device, combination products, botanicals). He works closely with physicians and naturopathic physicians in these clinical areas. He spent 6 years as the Co-Chair and member of Health Canada's Expert Advisory Committee for Veterinary Natural Health Products and Low Risk VHP. He was the Program Director of MDS Pharma Services. Dr. Chamberland has over 7 years experience in the development of clinical research protocols for botanical medicines and the management of these clinical studies in the areas of anxiety, sleep, pain, depression, inflammation and wound healing. He has over 22 years’ experience in the development of new drugs in the pharmaceutical industry (Canada and USA). He was a member of the Investment Committee of Fonds Bionovation for 7 years. Since 2007, Dr. Chamberland developed an expertise in botanical medicine and publishes a monthly column on natural alternatives for Oilfield Pulse Magazine and other health magazines. He gives lectures and continuing education workshops for health professionals (physicians, naturopathic physicians, chiropractors, etc) on the use of plants in the treatment of pain, anxiety, insomnia, wound healing etc. He got two patents (Patent granted on the synergy of phyto-ingredients.). He is the Professor of Botanical Medicine and Principles of clinical research at the Ecole d'Enseignement Superieur de Naturopathie du Quebec (EESNQ) and French language equivalent of the Canadian College of Naturopathic Medicine (CCNNM). He earned a diploma in Proficiency in Herbal Prescription from the Australian College of Phytotherapy, a Certified Herbalist from the Dominion College of Canada and a Master Herbalist diploma from the Dominion College of Canada. Dr. Chamberland received a B.Sc. in Agriculture from McGill University, an M.Sc. in Veterinary anatomy and physiology and a Ph.D. in Biomedical Sciences (toxicology) from the University of Montreal.
Bernard Lessard , MBA, CPA, CMA
Chief Financial Officer
Mr. Lessard has considerable experience as an executive in the life sciences sector serving as a member of the c-suite and as a trusted advisor to the board of directors in managing business strategy and research teams. He has been involved in numerous financings and the establishment of venture capital funds for start up companies in Quebec, dedicated to the life sciences sector. He launched a new biotech start-up as CEO of the organization and has held the role of portfolio manager in helping companies finance their future growth and as a special project director to implement business turnarounds. He has considerable experience as a CFO in risk management and he has successfully managed the mergers and acquisitions process of various companies while enhancing the assets of these organizations. He has considerable political connections with the Quebec government where he has served as a policy advisor with various Quebec government ministers with a specific mandate involving intellectual property and venture capital as a market strategy for the life sciences sector.
Vice President, Sales
Mr. Courchesne has over 25 years’ sales and management experience in the retail environment working for various companies such as Evian Spring Water (Danone) and Pfizer Canada. In the last 15 years, he has been working in both the pharmacy and health food channels where he successfully held positions in Quebec as National Sales Manager. In his previous companies, he rapidly reorganized the sales forces enabling the teams to outperform their sales and profit objectives. Since 2010 Mr. Courchesne has been working as an independent consultant helping various brands in many aspects of their business such as marketing, strategy and goal establishment while enabling them to solidify their presence at store level.
Vice President, Finance & Business Development
Mr. Béchard during his tenure at RBC Lifesciences Funds I&II, Mr. Béchard was a member of the Senior Management team that delivered top quartile returns in two separate funds. RBC Lifesciences. During his 12-year term as a venture capitalist Mr. Béchard, made numerous investments, sat on the boards of more than 25 life science companies and was actively involved in the negotiation of numerous strategic alliances, partnerships, and outright sales to both pharmaceutical and biotech companies. As a Board member he played an active role in the negotiation of numerous exits and was also actively involved in taking several companies public in Canada and the U.S. In his two operating roles, he was instrumental in contributing to the growth of two companies actively involved in developing pharmaceuticals. As a consultant to the biopharmaceutical industry Mr. Béchard provided start-up companies with assistance in the areas of fundraising, business development and corporate development.
DVM, Vice President, Marketing & Communication
Dr. Courtois has been working in the pharmaceutical industry for over 10 years in Europe and North America. She held the role as Director of Marketing and Scientific Affairs at Jamp Pharma (generic division) and Orimed Pharma (medical division) for over 4 years where she successfully led the marketing team to a 150% growth in sales while preparing the strategic plans for the medical and generic divisions. She managed the marketing of the fastest growing Canadian generic company which launched over 120 products in that time. In addition, she managed the marketing of the medical division, successfully launching over 10 branded products, prescription and OTC under medical recommendation, in a wide diversity of therapeutic areas (osteoporosis, sexual dysfunction, pain management and vitamin deficiency). She has international experience managing product lines and scientific and commercial training of multiple sales teams across Canada, USA and Europe in retail with natural health products, generics and prescription brands. Dr. Courtois has been very effective in launching products faster and efficiently as a member of the operations go-to-market team. Her core expertise is building brands with a strong identity that have a credible scientific background while fulfilling an unmet need on the market for patients and health care professionals. Dr. Courtois is a veterinary doctor and holds a Specialized Masters in management and entrepreneurship from HEC Paris.